癌症病人靜脈血栓栓塞藥物治療與預防的選擇
杜詩芸， 鄭閎文， 黃俊彥 - 澄清醫護管理雜誌, 2021 - airitilibrary.com
… Venous thromboembolism (VTE) is a common complication in … ), direct oral anticoagulants
(DOACs) can also be used to treat VTE in patients with active or inactive cancer. The choice of …
(DOACs) can also be used to treat VTE in patients with active or inactive cancer. The choice of …
直接口服抗凝血劑在癌症相關靜脈血栓栓塞治療的角色
張美惠， 林鴻銓， 蔡慈貞 - 腫瘤護理雜誌, 2017 - airitilibrary.com
… benefit and risk, tolerability, patient preference and cancer activity. Recently, the direct oral
anticoagulants (DOACs) are rapidly replacing VKA for the treatment of VTE in the general …
anticoagulants (DOACs) are rapidly replacing VKA for the treatment of VTE in the general …
[HTML][HTML] 《 胸部恶性肿瘤围术期静脉血栓栓塞症预防中国专家共识（ 2018 版）》 解读之直接口服抗凝药应用前瞻篇
姜瑞恒， 李彤， 李辉 - Chinese Journal of Lung Cancer, 2019 - ncbi.nlm.nih.gov
… direct oral anticoagulants and analyze the prospect of their perioperative application in
patients with … in Thoracic Surgery Perioperative venous thromboembolism (VTE) prophylaxis in …
patients with … in Thoracic Surgery Perioperative venous thromboembolism (VTE) prophylaxis in …
抗凝药物在肿瘤相关血栓栓塞性疾病中的应用研究进展
夏云龙， 吕海辰 - 药学进展, 2018 - pps.cpu.edu.cn
… 口服抗凝药(direct oral anticoagulant,DOAC), 即新型口服抗凝药(new oral anticoagulant,NOAC), …
-weight heparins for the prevention of recurrent venous thromboembolism in patients with …
-weight heparins for the prevention of recurrent venous thromboembolism in patients with …
肿瘤患者静脉血栓栓塞症的风险评估模型及其应用
韩森， 马旭， 方健 - 肿瘤防治研究, 2020 - zlfzyj.com
… A modified Khorana risk assessment score for venous thromboembolism in cancer
patients receiving chemotherapy: the Protect score[J]. Intern Emerg Med, 2012, 7(3): 291-292. …
patients receiving chemotherapy: the Protect score[J]. Intern Emerg Med, 2012, 7(3): 291-292. …
肺癌患者静脉血栓栓塞预防的疗效与安全性的meta 分析
苏俐玫， 毛溪悦， 阳丽梅 - 中国药学(英文版), 2023 - jcps.bjmu.edu.cn
… death among cancer patients[1,2]. The risk of venous thromboembolism (VTE) in lung cancer,
… Despite the wide use of new oral anticoagulants (NOACs) in patients with VTE, including …
… Despite the wide use of new oral anticoagulants (NOACs) in patients with VTE, including …
在癌症和非癌症患者中非维生素K 拮抗剂口服抗凝药的相对效益分析: 随机对照试验的Meta 分析
王晨曦， 杨萍萍， 李忠城， 邬涛， 吴清华 - 临床心血管病杂志, 2020 - lcxxg.whuhzzs.com
… overview of direct oral anticoagulants for the management of venous thromboembolism[J].…
molecular weight heparin in patients with cancer with venous thromboembolism:results of a …
molecular weight heparin in patients with cancer with venous thromboembolism:results of a …
《 多发性骨髓瘤相关静脉血栓栓塞症防治中国专家共识(2022 年版)》 解读
唐亮， 胡豫 - 临床血液学杂志, 2023 - lcxy.whuhzzs.com
… Venous thromboembolism (VTE) is one of the common complications of MM, and the key is
prevention, early diagnosis, and early treatment. However, there has been a lack of relevant …
prevention, early diagnosis, and early treatment. However, there has been a lack of relevant …
淋巴瘤患者静脉血栓栓塞症的研究进展
兰映霞， 张翼鷟 - 肿瘤防治研究, 2020 - zlfzyj.com
… 口服抗凝药 物(direct oral anticoagulants, DOACs)较LMWH可 … for venous thromboembolism
and mortality in patients treated … marker for venous thromboembolism in patients treated for …
and mortality in patients treated … marker for venous thromboembolism in patients treated for …